Stifel Nicolaus Keeps Their Buy Rating on Cara Therapeutics (CARA)

Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Cara Therapeutics (NASDAQ: CARA) yesterday and set a price target of $26. The company’s shares closed yesterday at $17.97.

According to TipRanks.com, Samimy is a 4-star analyst with an average return of 10.8% and a 52.4% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Jazz Pharmaceuticals, and TherapeuticsMD.

Currently, the analyst consensus on Cara Therapeutics is a Strong Buy with an average price target of $26.

See today’s analyst top recommended stocks >>

Based on Cara Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $17.19 million. In comparison, last year the company had a GAAP net loss of $9.3 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CARA Therapeutics, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain.